The Costa Rican Vaccine Trial is a longstanding collaboration between investigators in Costa Rica and NCI. The trial is funded by NCI and conducted in agreement with the Ministry of Health of Costa Rica. Vaccine was provided for our trial by GSK 20
Abstract
We compared two consensus primer PCR HPV genotyping methods for the detection of individual human papillomavirus (HPV) genotypes and carcinogenic HPV genotypes as a group, using a stratified sample of enrollment cervical specimens from sexually active women participating in the NCI/Costa Rica HPV 16/18 Vaccine Efficacy Trial. The SPF 10 method 5 extracted the DNA from 0.1% of the cervical specimen using a MagNA Pure LC instrument, targeted a 65 base pair region of the HPV L1 gene for PCR amplification using SPF 10 primers, and detected 25 genotypes by reverse line blot hybridization of the amplicons. The Linear Array (LA) method extracted the DNA from 0.5% of the cervical specimen using a MDx robot, targeted a 450 base pair region of the HPV L1 gene for PCR amplification using PGMY09/11 L1 10 primers, and detected 37 genotypes by reverse line blot hybridization of the amplicons. Specimens (n = 1,427) for testing by the LA method were randomly selected from strata defined based on enrollment test results from the SPF 10 method, cytology, and Hybrid Capture 2. LA results were extrapolated to the trial cohort (n = 5,659). LA and SPF 10 considered the carcinogenic HPV genotypes. There was no difference in the overall grouped detection of carcinogenic HPV by the SPF 10 and LA methods (35.3% vs. 35 .9%, respectively, p = 0.5), with a 91.8% overall agreement and kappa of 0.82. In comparisons of individual HPV genotypes, the LA method detected significantly more HPV16, HPV18, HPV39, HPV58, HPV59, HPV66, and HPV68/73 and less HPV31 and HPV52 than the SPF 10 method; inclusion 20 of genotype-specific testing for HPV16 and HPV18 for those SPF 10 method HPV positives for which no HPV genotype was detected abrogated any differences between LA method and SPF 10 method. The LA method detected more carcinogenic HPV genotypes infections per specimen than the SPF 10 method (p < 0.001). In conclusion, the LA method and the SPF10 method with HPV16 and HPV18 genotype-specific detection among un-genotyped HPV positives were 25 comparable for detection of HPV16 and HPV18, the two HPV genotypes targeted by current prophylactic HPV vaccines. Both approaches are suitable for monitoring the impact of HPV16/18 vaccines in clinical trials. 
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INTRODUCTION
It is now well-established and widely accepted that virtually all cervical cancer and its immediate precancerous lesions are caused by persisting cervical infections by approximately 15 cancerassociated (carcinogenic) human papillomavirus (HPV) genotypes (20, 34, 37) . The most 5 important of these HPV genotypes are HPV16 and HPV18, which account for approximately 70% of all cancer of the cervix, with minor variations between continents (29) . Prophylactic HPV vaccines targeting HPV16 and HPV18 have shown better than 90% efficacy for preventing persistent infections and cervical precancer caused by these genotypes in women not already infected with these genotypes (1, 8, 21 ) 10
Critical to large-scale evaluations of these and future HPV vaccines is the genotype-specific measurement of HPV infections, particularly HPV16 and HPV18, to define genotype-specific endpoints of HPV persistence and cervical precancer (cervical intraepithelial neoplasia grade 2
[CIN2] and grade 3 [CIN3]). We have primarily relied on a PCR method based on SPF 10 LiPA 25 15 (16, 17) to measure HPV genotypes in a large, community-based phase III clinical trial of approximately 7,500 women ages 18-25 living in Guanacaste, Costa Rica (14, 25) . We recently demonstrated that detection of carcinogenic HPV by SPF 10 LiPA 25 method was in good concordance with hc2 (Qiagen, Gaithersburg, MD, USA) (25) , an FDA-approved test for carcinogenic HPV. However, hc2 does not distinguish which specific carcinogenic HPV 20 genotype(s) is present and therefore we could not evaluate the performance of the SPF 10 LiPA 25 system for detection of individual HPV genotypes.
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on November 13, 2017 by guest http://jcm.asm.org/ Downloaded from 6 We were therefore interested in further validating the use of SPF 10 LiPA 25 in our trial by a posthoc comparison to another PCR-based HPV genotyping method, Linear Array (LA; Roche Molecular Systems), which uses PGMY09/11 L1 consensus primers (10) . PCR methods using PGMY09/11 primers have been extensively used in epidemiologic studies of HPV (9, 23, 24, 27, 31, 35) . This PGMY-based method detects 37 HPV genotypes, including all known 5 carcinogenic HPV genotypes. We have recently completed several validation studies of this PGMY-based method showing good analytic and clinical performance (4, 5, 11) . Our primary objective in this analysis was to compare HPV genotyping results from these two protocols/methods, one based on the PGMY primers and the other based on the SPF 10 primers, by testing a set of baseline, pre-randomization cervical specimens from a stratified random 10 sample of women enrolled in the vaccine trial. 

METHODS
Study Population
The primary aim of the Costa Rica Vaccine Trial is to independently assess the efficacy of an This analysis was based on the enrollment, pre-vaccination specimens from women entering the 15 vaccine trial. All study protocols were reviewed and approved by the NCI and a Costa Rican Institutional Review Boards. All participants provided written, informed consent.
HPV Detection and Genotyping
20
Hybrid Capture 2 Testing. Hybrid Capture 2 is a clinical test that collectively targets 13 carcinogenic HPV genotypes (16, 18, 31, 33, 35, 39, 45 , 51, 52, 56, 58, 59 and 68) without
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SPF 10 /LIPA 25 Testing. Total DNA was isolated from 200 µL of one of the 500 µL PC aliquots using the MagNA Pure LC instrument (Roche Diagnostics, Almere, the Netherlands), using the 5 Total DNA isolation kit (Roche Diagnostics). DNA was eluted in 100 µL of water. Each DNA extraction run contained positive and negative controls to monitor the DNA isolation procedure.
A 10 µL aliquot of extracted DNA was used for each SPF PCR reaction (4% of the 500 µL aliquot or 0.1% of the entire specimen). The SPF 10 PCR primer set (DDL Diagnostic 10 Laboratory, Voorburg, The Netherlands) was used to amplify a broad spectrum of HPV genotypes as described earlier (16, 17) . Briefly, this primer set amplifies a small fragment of 65 base pairs from the L1 region of HPV. The reverse primers contain a biotin label at the 5' end, enabling the capture of the PCR amplicon onto streptavidin-coated microtiter plate wells. Genotype-Specific HPV Testing. Because the vaccine trial is using a bivalent, HPV16/18 10 vaccine, genotype-specific (TS) PCR primer sets were also used to optimize the detection of these two HPV genotypes. Specimens that tested positive by SPF 10 but did not contain HPV16 or HPV18 using LiPA 25 were selectively amplified for HPV16 (TS16) and HPV18 (TS18) (32) .
The genotype-specific primers were based on those described by Baay et al. (2) ; they generate amplicons of 92 and 126 base pairs for HPV16 and HPV18, respectively. Amplicons from the 15 TS-PCRs were detected by DEIA, similar to the method for SPF 10 amplicon detection.
LA Testing. The second 500 µL aliquot of PC was used for testing by LA, a commercialized, research-use only L1 consensus primer-based PCR method that employs a primer set designated PGMY09/11 (10) . LA testing was done masked to the all other data. Amplicons were subjected 20 to reverse-line blot hybridization for detection of 37 individual HPV genotypes (HPV 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, (51) (52) (53) (54) (55) (56) 58, 59 , 61, 62, 64, 66-73, 81-4, 82v, 89) (10, 22) . 35 , and/or 58 and the HPVmix have an uncertain HPV52 status, and for this analysis these specimens were considered to be HPV52 5 negative. LA was used according to the manufacturer's instructions in the product insert, which includes DNA extraction using the QIAamp MinElute Media Kit (QIAGEN, Inc., Valencia, CA).
The only deviation from the LA product insert protocol was to implement an automated sample preparation for extraction of up to 96 specimens at a time on the QIAGEN MDx platform (using the MinElute Media MDx Kit and manufacturer's instructions) rather than processing 24 10 specimens per batch with the manual vacuum method (4, 11) . LA testing used 21% of the aliquot or 0.5% of the entire specimen.
It is noteworthy that the primers used for amplification and amplicon detection method were not the only differences between methods. Each method used different extraction methods and 15 different amounts of purified DNA in the PCR reaction as well as different primers and methods of amplicon detection. To reflect that no single component in each method was comparable, we will henceforth refer to MagNa Pure DNA extraction, SPF 10 primer PCR amplification, and LiPA 25 HPV genotype detection as the "SPF 10 method" and the MDx DNA extraction, PGMY09/11 primer PCR amplification, and LA HPV genotype detection as the "LA method". 20
Statistical Analysis
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The SPF 10 method results were available for all 5,871 sexually experienced women enrolled in CVT. At the time of selecting aliquots testing by the LA method, 5,659 (96%) of the specimens had been tested by the SPF 10 method and thus defined our analytic sample. A stratified random sample of 1,508 specimens was selected based on the SPF 10 method, hc2, and cytology results as shown in Table 1 to over-sample for cytologic abnormalities and discordant test results (e.g., 5
hc2-positive/ SPF 10 method negative/LSIL cytology). We sampled the least from common categories such as hc2-negative/SPF 10 method negative/negative cytology and hc2-positive/ SPF 10 method positive for carcinogenic HPV/negative cytology. One batch of 81 aliquots selected for LA method testing was lost due to DNA extraction robot failure and thus a total of 1,427 specimens (95% of the selected aliquots and 25% of the analytic sample) had results for 10 both the SPF 10 and LA methods for a direct comparison. Unless specified, HPV16 and HPV18 genotype-specific PCR testing results were not used in our comparison of the SPF 10 and LA methods.
To account for using a stratified random sample based partially on the SPF 10 The results of both HPV genotyping methods were compared by calculating percent overall agreement, agreement on testing positive, kappa, and tested for statistical differences (p < 0.05) using an exact symmetry or McNemar's χ 2 test. Each analysis was based on weighting each of the 1427 results by the inverse of the probability of sampling each for testing stratified on hc2 5 result, cytology, and the SPF 10 method result ( Table 1 ). The sampling weights were accounted in the testing and variance estimation with a leave-one-out jackknife variance estimator (18) .
RESULTS
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Detection of carcinogenic HPV. We first compared the detection of any carcinogenic HPV genotype by the two HPV genotyping methods as shown in Table 2 . There was no difference in the detection of one or more carcinogenic HPV genotypes by the two methods, 35.3% by the SPF 10 method and 35.9% by the LA method (p = 0.5), with a 91.8% overall group agreement, 79.3% agreement on testing positive, and a kappa of 0.82. There were no significant differences 15 in the overall detection of carcinogenic HPV for the two methods stratified on hc2 test results
(negative vs. positive) or cytologic interpretation (normal cytology vs. ≥ASC-US).
There was also no difference in the detection of all HPV considered as a group (including SPF 10 /DEIA positive/LiPA negatives) (p = 0.8) and detection of one or more HPV genotypes 20 targeted by both methods (p = 1.0) ( Table 2) . Table 3 . The LA method also detected more combined HPV16 and HPV18 (10.7%) than the SPF 10 method (9.6%) (p = 0.01). For other genotypes targeted by both methods, the LA method detected significantly more HPV40, 5 HPV42, HPV54, and HPV70 and less HPV11 than the SPF 10 method. While the overall agreement for individual HPV genotypes targeted by both methods was 95% or greater, the agreement on testing positive ranged from 82.0% for HPV16 to 6.1% for HPV42, which was very uncommonly detected by the SPF 10 method.
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The testing algorithm for CVT includes HPV16 and HPV18 genotype-specific PCR testing.
Combining the results of genotype-specific PCR testing with the SPF 10 method for detection of HPV16 and HPV18, we found no differences in the detection of HPV16/18 by the combined testing compared to the LA method (10.8% vs. 10.7%, respectively) (p = 0.6). The overall agreement was 98.3%, agreement on testing positive was 85.6%, and the kappa was 0.91. 15
Of the additional 27 HPV16 positives detected by the LA method compared to the SPF 10 method in the crude results for the 1,427 paired tests, 19 (70.3%) were confirmed by HPV16 genotypespecific testing. Of the additional 26 HPV18 positives detected by the LA method compared to the SPF 10 method, 12 (46.2%) were confirmed by HPV18 genotype-specific testing. 20
The SPF 10 method is sometimes HPV positive by DEIA but no HPV genotype was identified by LiPA 25 . As shown in Table 4 Table) . We identified a HPV genotype in 63 of 81 specimens (78%). The most common HPV genotypes detected by sequencing SPF 10 -positives, LiPA 25 -negative specimens were HPV30 (n = 15, 19%) (a HPV genotype not detected by the LA method), HPV61 (n = 11, 14%) (9 out of 11 confirmed by the LA method), and HPV67 (n = 8, 10%) (8 of 8 were confirmed by the LA method). 15
Comparing the two HPV genotyping methods permitted us to examine the indirect strategy used by the LA method to detect HPV52, i.e., specimens that test positive for a pool of HPV genotype probes, which are specific for HPV33, HPV35, and HPV58 and cross-reacts with HPV52, but test negative for HPV33, HPV35, and HPV58 individually are assumed to be HPV52 positive. 20 We observed that 70.5% of those inferred as HPV52 positive by the LA method were confirmed by the SPF 10 method ( Table 5, Table 6 ). The SPF 10 method was 10 more apt to test positive for HPV68/73 among those specimens that tested LA method positive for HPV68 and negative for HPV73 than negative for HPV68 and positive for HPV73 (60% vs.
35.6%, respectively, p = 0.04). Similar patterns were observed among those with normal cytology and with non-normal cytology (≥ASC-US) (data not shown) (n.b., because hc2 is designed to detect HPV68 but not HPV73, we did not use it to stratify the paired results). 15
However, among the SPF 10 method positives for HPV68/73, a greater fraction were positive for HPV73 by the LA method alone than for HPV68, 37.5% vs. 32.1%.
Number of carcinogenic HPV genotypes. There was 82.4% overall agreement between the two methods for the number of carcinogenic HPV genotypes ( Table 7) , with a kappa of 0.67 and a 20 linearly-weighted kappa of 0.74. The LA method detected more carcinogenic HPV genotypes infections per specimen than the SPF 10 method (p < 0.001); the LA method detected more infections with two or more carcinogenic HPV genotypes (15.4% vs. 11.8%) and more infections
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HPV risk groups.
Categorizing results according to the risk groups as described in the methods (Table 8) , there was an 83.3% overall agreement and an 86.9% agreement among specimens HPV positive by both methods. The LA method had a tendency to categorize women into a higher risk group than the SPF 10 method (p < 0.001), primarily because the LA method classified 10 more women as HPV16 (n = 437) or HPV18 positive (n = 167) than the SPF 10 method (n = 404 for HPV16 and n = 141 for HPV18). This was mainly the result of the LA method reclassifying carcinogenic HPV-positive women by the SPF 10 method as HPV16 positive (n = 33) or as HPV18 positive (n = 37) whereas the SPF 10 method reclassifying the LA method results was relatively uncommon (n = 5 for HPV16 and n = 2 for HPV18). Restricted to results in which 15 both tests were positive for carcinogenic HPV, the LA method was still more likely to categorize the individual test results into a riskier category (HPV16 or HPV18) than the SPF 10 method (p < 0.001).
DISCUSSION 20
We evaluated two PCR methods of HPV genotyping based on two well-established primers, SPF 10 and PGMY09/11, with the following goals. First, we were interested in further validating (12) and confirmed here, each method has its own idiosyncrasies. Theoretically, data such as we present here can be used to adjust for 10 differences between methods and better allow data to be combined in meta-analyses when two methods with different strengths and weaknesses are used.
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We again emphasize that we compared two HPV genotyping methods, not just different primer systems, and these methods differed in the following ways: 1) DNA extraction and purification 15 (MDx for the LA method vs. MagnaPure LC for the SPF 10 method); 2) the amount of purified DNA amplified (0.5% for the LA method vs. 0.1% for the SPF 10 method); 3) PCR primers (PGM09/11 for the LA method vs. SPF 10 for the SPF 10 method); and 4) method of amplicon detection (Linear Array for the LA method vs. LiPA 25 for the SPF 10 method). In general, we found the performance for both methods very similar for the overall detection of carcinogenic 20 HPV, as has been previously reported on smaller set of specimens (33) . However, for individual HPV genotypes, the LA method detected more HPV16, HPV18, HPV39, HPV58, HPV59, HPV66, and HPV68/73 while the SPF 10 method detected more HPV11, HPV31, and HPV52.
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We also observed that LA method was able to detect more multi-genotype infections and a greater number of HPV genotypes per multi-genotype infection than the SPF 10 method. The increased detection of multi-genotype infections by the LA method compared to the SPF 10 method could be the result of false positives or increased analytic sensitivity. However, 340 of 5 577 (58.9%) of additional HPV genotypes detected by the LA method were judged (P.E.G.) to have a HPV genotype band strength of 3 or 4 (on a 1-4 scale, with 1 being the weakest and 4 being the strongest), suggesting that at least a portion of the additional pick-ups were true positives. At this time, we cannot attribute these differences in detection between HPV genotyping methods to any one procedural step. 10 We note that one previous study compared these PCR primer systems using the same input amount of DNA (0.1% of a PreservCyt specimen) from the same extraction and found more similar results (33) than observed here, providing more evidence of the importance of standardization and optimization of the front-end (e.g., DNA purity and quantity) of these 15 methods on their performance (7) . Yet, in this previous report (33) , there were still differences even when controlling for DNA purity and quantity, with LA detecting marginally more HPV16 and HPV59 and detecting marginally less HPV51 than SPF 10 LiPA 25 . Thus, each step in a PCRbased HPV genotyping method (DNA extraction, DNA input, primers, and amplicon detection) influences the test results and must be taken into consideration in any evaluation of method 20 performance. We plan to explore the impact of these parameters on the test performance of the two HPV genotyping methods in subsequent discrepancy analyses, which should also address any possible false positive/negative results by either assay.
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We found the SPF 10 method used in this study detected slightly less HPV16 and HPV18 than the LA method but the difference, albeit statistically significant, was small. Combining HPV16-and HPV18-genotype specific PCR assays with the SPF 10 Because the median and mean age of the women participating in this HPV vaccine trial was only 21 years of age, there were few cases of confirmed CIN2 or worse (≥CIN2) (CIN2, n = 14; 5 CIN3, n = 26), limiting the analytic power to assess clinical sensitivity. Although precancerous lesions in young women tend to be smaller than those diagnosed in older women (28), 97.5% and 100% of the ≥CIN2 tested positive for carcinogenic HPV by the SPF 10 method and the LA method, respectively, and 100% of the CIN3 tested positive for carcinogenic HPV by both methods. 10
The optimal clinical application of HPV genotyping in cervical cancer screening and clinical management decisions has yet to be determined. There is evidence that individual detection of HPV16 and HPV18 may be useful for deciding who among carcinogenic HPV-positive, cytologically-negative women might benefit from immediate colposcopy (HPV16 and/or HPV18 15 positive) versus one-year follow-up (HPV16 and HPV18 negative) (15, 36) . There is increasing evidence that detection of viral persistence over a year or two could be clinically-useful (3, 19) for identifying women at risk of cervical precancer and cancer, but the best format for those tests (e.g., partial versus full HPV genotyping) requires additional evaluations (3).
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Our analysis was limited by the complex sampling based on SPF 10 method, hc2, and cytology results that were used to define the subset of specimens for LA testing, weighting in favor of the most informative specimens. As consequence, we could only estimate by extrapolation the method results from the 1,427 tests within the sampling scheme to the full cohort of 5,659 agreed well with the empirical testing results for the full cohort of 5,659, which suggest that our estimates for the LA method are fairly accurate. Nonetheless, we acknowledge that our methods may have led to small errors in our evaluation of the LA method. 5 We conclude that both HPV genotyping methods showed excellent agreement for common HPV genotypes detected in baseline cervical specimens collected from women participating in the HPV vaccine trial. Based on these data, we suggest that the use of the both methods will provide an accurate estimate for the main outcomes in HPV vaccine trials, and both will be useful in 10 studies of the natural history of HPV. Each test has its strengths and weaknesses, including differences in detection of individual HPV genotypes, and these differences should be considered when choosing a method of HPV genotyping for a specific application. 
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